| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| NVS | Novartis AG | $85.13 | $197.65B | N/A |
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More
http://www.zacks.com/stock/news/577360/drug-biotech-stock-q3-earnings-on-oct-23-lly-alxn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-577360
Oct 22, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
0
Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y
http://www.zacks.com/stock/news/577246/novartis-nvs-q3-earnings-sales-beat-estimates-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-577246
Oct 22, 2019 - Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.
0
Are You Looking for a Top Momentum Pick? Why Euronav NV (EURN) is a Great Choice
http://www.zacks.com/stock/news/575334/are-you-looking-for-a-top-momentum-pick-why-euronav-nv-eurn-is-a-great-choice?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-575334
Oct 21, 2019 - Does Euronav NV (EURN) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Schlumberger NV (SLB) Q3 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/10/18/schlumberger-nv-slb-q3-2019-earnings-call-transcri.aspx?source=iedfolrf0000001
Oct 18, 2019 - SLB earnings call for the period ending September 30, 2019.
0
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings
http://www.zacks.com/stock/news/571262/factors-setting-the-tone-for-novartis-nvs-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-571262
Oct 18, 2019 - Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.
0
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
http://www.zacks.com/stock/news/569743/novartis-jakavi-meets-primary-goal-in-phase-iii-for-gvhd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-569743
Oct 17, 2019 - Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
0
Roche Posts Solid Sales for First 9 Months of '19, Ups View
http://www.zacks.com/stock/news/569605/roche-posts-solid-sales-for-first-9-months-of-19-ups-view?cid=CS-ZC-FT-analyst_blog|earnings_article-569605
Oct 17, 2019 - Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.
0
ASML HOLDING NV (ASML) Q3 2019 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2019/10/16/asml-holding-nv-asml-q3-2019-earnings-call-transcr.aspx?source=iedfolrf0000001
Oct 16, 2019 - ASML earnings call for the period ending September 29, 2019.
0
Roche Announces Positive Late-Stage Data on Rituxan in PV
http://www.zacks.com/stock/news/563858/roche-announces-positive-late-stage-data-on-rituxan-in-pv?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563858
Oct 14, 2019 - Roche (RHHBY) announces positive late-stage data on Rituxan for the treatment of moderate to severe PV.
0
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-559573
Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
0
Page 1>